Ann Hanham is Director at ENDOCYTE INC (ECYT). They have made 8 open-market trades across 2 companies since 2012, most recently 2026-06-26.
CIK 0001286338
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $15K since 2016, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SCYX | BUY | 2016-05-25 | 2016-05-27 | $3.64 | $15K | -18.8% | -44.5% | -26.8% |
| ECYT | SELL | 2013-05-24 | 2013-05-29 | $14.10 | $140K | -24.6% | -0.5% | -0.5% |
| ECYT | SELL | 2013-05-20 | 2013-05-22 | $14.38 | $575K | -24.6% | -0.5% | -0.5% |
| ECYT | SELL | 2013-05-16 | 2013-05-20 | $14.41 | $536K | -24.6% | -0.5% | -0.5% |
| ECYT | SELL | 2013-05-14 | 2013-05-16 | $14.69 | $590K | -24.6% | -0.5% | -0.5% |
| ECYT | SELL | 2012-06-05 | 2012-06-07 | $6.60 | $2.1M | -24.6% | -0.5% | -0.5% |
| ECYT | SELL | 2012-05-16 | 2012-06-04 | $6.65 | $186K | -24.6% | -0.5% | -0.5% |
| ECYT | SELL | 2012-05-14 | 2012-05-16 | $6.87 | $1.0M | -24.6% | -0.5% | -0.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.